Table 2.
Studies including ≥5 patients with CNS disease and reported data on ICANS.
| References | Type of study | Type of CAR-T | N | CNS disease (localization) | ICANS Severity n/total (%) |
|---|---|---|---|---|---|
| Abramson et al. (11) | Clinical trial | Liso-cel | 7 | SCNSL | 2/7 (29 %) 2/2 (100 %) |
| Ahmed et al. (67) | Single-center retrospective | Axi-cel (3) Tisa-cel (4) | 7 | SCNSL 5 parenchyma/2 lepto | 3/7 (42.8 %) 1/3 (33.3%) |
| Alcantara et al. (68) | Multicenter retrospective | Axi-cel (2) Tisa-cel (7) | 9 | PCNSL 8 parenchyma/1 lepto | 5/9 (55.5%) 2/5 (40%) |
| Ayuk et al. (69) | Multicenter retrospective | Axi-cel (14) Tisa-cel (14) | 28 | SCNSL 16 parenchyma/6 lepto/6 both | 13/28 (46%) 4/13 (31%) |
| Bennani et al. (70) | Multicenter retrospective | Axi-cel | 15 | SCNSL 4 parenchyma/10 lepto/1 NA | 13/15 (87%) 5/13 (38.4%) |
| Frigault et al. (71) | Single-center retrospective | Tisa-cel | 8 | SCNSL 3 parenchyma/3 lepto/2 both | 3/8 (37.5%) 0/3 (0%) |
| Frigault et al. (36) | Phase I/II trial | Tisa-cel | 12 | PCNSL 10 parenchyma/2 lepto | 6/12 (50%) 1/6 (16.6%) |
| Ghafouri et al. (72) | Single-center retrospective | Axi- or Tisa-cel | 7 | SCNSL 7 parenchyma/2 lepto | 4/7 (57%) 2/4 (50%) |
| Jacobson et al. (73) | Pilot trial | Axi-cel | 8* | 6 PCNSL/3 SCNSL 8 parenchymal only | 4/8 (50%) 3/4 (75%) |
| Jacoby et al. (74) | Multicenter retrospective | CD-19 | 55 | ALL 16/55 active CNS | 21/55 (38%) 6/21 (28.5%) |
| Karschnia et al. (75) | Single-center retrospective | CD19 | 10 | SCNSL 7 parenchyma/3 lepto | 6/10 (60%) 3/6 (50%) |
| Leahy et al. (76) | Post-hoc analysis | CD19 | 66 | B-ALL | 38/66 (57%) 8/38 (21%) |
| Li et al. (77) | Phase I trial | CD19 + CD22 | 5 | 1 PCNSL/4 SCNSL 4 parenchymal/1 both | 2/5 (40%) 1/2 (50%) |
| Liu et al. (78) | Single-center prospective | CD19 or CD20 | 7 | 1 PCNSL/6 SCNSL 5 parenchymal | 0/7 (0%) |
| Liu et al. (79) | Phase I trial | CD19-CD22 | 5* | Burkitt (5 evaluable safety) | 5/5 (100%) 3/5 (60 %) |
| Nastoupil et al. (80) | Multicenter retrospective | Axi-cel | 21 | SCNSL History of CNS disease | NA |
| Qi et al. (40) | Multicenter retrospective | CD19 | 48 | B-ALL | 18/48 (37.5%) 11/18 (61.1%) |
| Shalabi et al. (37) | Phase I trial | CD19/CD28 | 13 | B-cell leukemia 1 parenchymal | 5/13 (38.4%) 1/5 (20%) |
| Siddiqi et al. (38) | Retrospective phase I | CD19 | 5 | PCNSL | 5/5 (100%) 1/5 (20%) |
| Sylvain et al. (81) | Multicenter retrospective | Axi-cel (4) Tisa-cel (12) | 17 | PCNSL 13 parenchyma/4 lepto only | 9/17 (52.9%) 3/9 (33.3%) |
| Strati et al. (82) | Single-center retrospective | Axi-cel | 8 | SCNSL Prior CNS lymphoma | 8/8 (100%) 5/8 (62.5%) |
| Tan et al. (83) | Single-center retrospective | CD19 | 12 | B-ALL 1 parenchyma | 10/12 (83%) 4/10 (40%) |
| Wu et al. (84) | Single-center trial | CD19/22 | 13 | 4 PCNSL/9 SCNSL | 3/13 (27%) 1/3 (33.3%) |
| Xue et al. (85) | Single-center retrospective | CD19/20/22 | 17 | 2 PCNSL/15 SCNSL 13 parenchyma/7 lepto | 6/17 (35%) 5/6 (83.3 %) |
| Yuen et al. (86) | Multicenter retrospective | Axi-cel | 14 | SCNSL (7/14 active) (3 HIV+) | 6/14 (43%) 4/6 (66.66%) |
| Zhang et al. (87) | Multicenter retrospective | CD19/20/22 | 15 | SCNSL 10 parenchyma/6 lepto | 3/15 (20%) 1/3 (33.3%) |
SCNSL, secondary central nervous system lymphoma; PCNSL, primary central nervous system lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; NA, not available; HIV, human immunodeficiency virus. *Patients evaluable for safety.